Abstract
Psoriasis, atopic dermatitis, and skin cancer are the three main dermatological, highly prevalent diseases for which new effective systemic therapies have been developed. For the immune-mediated inflammatory skin diseases, several biologic agents are now available for the chronic plaque psoriasis. These agents target one specific proinflammatory cytokine (TNF-alpha, interleukin (IL)-17, and (IL)-23) or its receptor. The IL-4 receptor blocking dupilumab is the first biologic agent which can be used for the chronic inflammatory skin disease, atopic dermatitis. By interfering in the Hedgehog signaling pathway, vismodegib proves to be effective in metastasized or extensive basal cell carcinoma (BCC) where a surgical procedure is no longer feasible. Immunotherapy with checkpoint inhibitors is a major breakthrough in melanoma and is rewarded with the Nobel Prize in Physiology and medicine, 2018. All these new systemic therapies are valuable additions to the already existing armentarium of the dermatologist.
References and Further Reading
Abbasi NR et al (2004) Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 292(22):2771
Alam M, Ratner D (2001) Cutaneous squamous-cell carcinoma. N Engl J Med 344(13):975
Beck LA et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371(2):130
Bissonnette R et al (2016) Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 175(5):902–911
Boehncke WH, Schön MP (2015) Psoriasis. Lancet 386(9997):983–994
Boguniewicz M, Leung DY (2011) Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 242(1):233
Brodland DG, Zitelli JA (1992) Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol 27(2 Pt 1):241
Chapman PB et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507
Charman CR, Venn AJ, Williams HC (2004) The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol 140:1513–1519
Criscione VD et al (2009) Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 115(11):2523
Crowson AN (2006) Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 19:S127–S147
Eichenfield LF et al (2014) Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 71(1):116. Epub 2014 May 9
Ferrucci LM et al (2012) Indoor tanning and risk of early-onset basal cell carcinoma. J Am Acad Dermatol 67(4):552. Epub 2011 Dec 9
Flaherty KT et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694. Epub 2012 Sep 29
Gallagher RP et al (1995) Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol 131(2):157
Gaudy-Marqueste C et al (2017) Ugly duckling sign as a major factor of efficiency in melanoma detection. JAMA Dermatol 153(4):279
Gershenwald JE, Scolyer RA, Hess KR et al (2017) Melanoma of the skin. In: Amin MB (ed) AJCC cancer staging manual, 8th edn. American Joint Committee on Cancer, Chicago, p 563
Gorlin RJ, Goltz RW (1960) Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med 262:908
Guttman-Yassky E (2018) Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial. J Am Acad Dermatol 78(5):872–881
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M (2001) The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 10(1):11–18
Kuflik EG (2004) Cryosurgery for skin cancer: 30-year experience and cure rates. Dermatol Surg 30(2 Pt 2): 297
Larkin J et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23
Leung DY (2013) Why is eczema herpeticum unexpectedly rare? Antiviral Res 98(2):153–157. Epub 2013 Feb 22
Locke J et al (2001) Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys 51(3):748–755
Love WE et al (2009) Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 145(12):1431
Marks R, Whiteman D (1994) Sunburn and melanoma: how strong is the evidence? BMJ 308:75–76
Marsden JR et al (2010) Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 163(2):238. Epub 2010 Jul 1
Marzuka AG, Book SE (2015) Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med 88(2):167–179. eCollection 2015 Jun
Mason AR et al (2013) Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 3:CD005028
Menter A et al (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58(5):826
Menter A et al (2009) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 61(3):451
Morton CA et al (2013) European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications – actinic keratoses, Bowen’s disease, basal cell carcinoma. J Eur Acad Dermatol Venereol 27(5):536. Epub 2012 Nov 26
Nestle FO et al (2009) Psoriasis. N Engl J Med 361(5):496
Ports WC et al (2013) A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 169(1):137
Rastrelli M et al (2014) Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo 28(6):1005–1011
Ring J et al (2012) Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 26(9):1176–1193. Epub 2012 Jul 19
Rodrigues LK et al (2000) Fine needle aspiration in the diagnosis of metastatic melanoma. J Am Acad Dermatol 42(5 Pt 1):735
Rudikoff D, Lebwohl M (1998) Atopic dermatitis. Lancet 351(9117):1715
Ruzicka T et al (2017) Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med 376(9): 826–835
Schmitt J et al (2005) The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210(3):194–199
Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis (1993) Dermatology 186(1):23–31
Simpson EL et al (2018) Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 78(5):863–871
Thyssen JP, Kezic S (2014) Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 134(4):772–799
Tollefson MM, Bruckner AL (2014) Atopic dermatitis: skin-directed management. Pediatrics 134(6):e1735
Van Loo E et al (2014) Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer 50(17):3011–3020. Epub 2014 Sep 25
Weichenthal M et al (2005) Phototherapy: how does UV work? Photodermatol Photoimmunol Photomed 21(5): 260
Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD (2018) Atopic dermatitis. Nat Rev Dis Primers 4(1):1
Wong SL et al (2012) Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 30(23):2912
Yanofsky VR et al (2011) Histopathological variants of cutaneous squamous cell carcinoma: a review. J Skin Cancer 2011:210813. Epub 2010 Dec 29
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this entry
Cite this entry
Bik, L., Thio, H.B. (2019). Pharmacodynamic Evaluation: Dermatology. In: Hock, F., Gralinski, M. (eds) Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-319-56637-5_36-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56637-5_36-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56637-5
Online ISBN: 978-3-319-56637-5
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences